My comments at the FDA ODAC on MRD as an accelerated approval endpoint in Myeloma Safety is the big reason this is a bad decision

Some years ago, there was an excellent Plenary Session Podcast 🎙️ podcast that dived into the issue of PROs & whether patients even understood what they were being asked re: quality of life (they didn't). This study provides better context about the actual things that matter to patients:

Our latest paper led by med student Josh Elbaz👇 68% of cancer drug approvals don't have evidence they increase survival! Let me explain some key findings about the FDA #1. Both regular and accelerated approvals are based on surrogates... dx.doi.org/10.1002/cam4.7…

We are launching the editor's pick. Each Friday we will pick a seminal article and discuss it. Today is Aaron Goodman - “Papa Heme” And Manni Mohyuddin Timothée Olivier, MD Subscribe to the drug development letter drugdevletter.com/p/fridays-gem-…

A real honor to receive this teaching award!

How to present journal club 10 questions I ask when I read and interpret a cancer clinical trial! Full video on The Drug Development Letter Subscribe now for FREE Timothée Olivier, MD drugdevletter.com/p/how-to-do-a-…

Everyone who messaged me about this can come. I will tweet the room number out closer to the date. #asco24 #asco2024 Sorry I could not reply to all. Way more people than I thought. We're going to be doing live Plenary Session Podcast 🎙️ stuff.

The top 7 ASCO abstracts per Timothée Olivier, MD and me Subscribe to drugdevletter.com And Plenary Session Podcast 🎙️ for live updates from #ASCO24 #ASCO2024 What to look for... 30 min discussion worth your time!

James Caudell Vinay Prasad MD MPH ASCO Timothée Olivier, MD Plenary Session Podcast 🎙️ Thanks James Caudell - any word on whether investigators were blinded? If not, I am concerned about bias for 2 outcome of g tube placement as mentioned by Vinay Prasad MD MPH I am also not sure I can get over the non-inferiority design for a more expensive, less available modality.

Just OUT! Afatinib has been tested in 12 tumor types, but only approved in 1. After approval, the company tried it in many patients with poor response rate and high toxicity. The landscape of drug development is often predatory Collab with Vassar lab authors.elsevier.com/c/1jBbcXyUs8ozc

My 2 hour lecture on Critical Appraisal at #ASCO24 youtube.com/watch?v=0bVAlU…

All new Plenary Session Podcast 🎙️ episode 2 hour lecture given at #ASCO24 on critical appraisal soundcloud.com/plenarysession…

Plenary Session Podcast 🎙️ Video diaries of trial participants, those doing well and those dead. 💡🤯

If you would like to read medical papers better than the example below, read the essay by Manni Mohyuddin and I in JAMA Internal Medicine It is called Detecting Selection Bias in Observational Studies—When Interventions Work Too Fast jamanetwork.com/journals/jamai…

Post ASCO wrap up now on Plenary Session Podcast 🎙️ Vinay Prasad MD MPH VKPrasadLab Timothée Olivier, MD soundcloud.com/plenarysession…

Post ASCO updates with Timothée Olivier, MD and me Subscribe to drugdevletter.com for free updates Also on Youtube and Plenary Session Podcast 🎙️ VKPrasadLab Sensible Medicine

Biden's mental health Is it Parkinsonism or a stutter? Normal aging or lewy body dementia? Cold medication AEs or vascular dementia? Politics vs. Medicine youtu.be/l5hoMxumj_8

I have a long video on Mammography from the days of long hair Gets into all the data youtube.com/watch?v=-9hQO7…

Things we can learn about driver mutation lung cancer #sotorasib Plenary Session Podcast 🎙️

How we can do better at a county hospital (8/30/24 lecture) Oncology/ Screening/ Drugs that Don't Work & More